|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: THPO |
Gene summary for THPO |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | THPO | Gene ID | 7066 |
| Gene name | thrombopoietin | |
| Gene Alias | MGDF | |
| Cytomap | 3q27.1 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P40225 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7066 | THPO | HCC1_Meng | Human | Liver | HCC | 3.29e-56 | 1.91e-01 | 0.0246 |
| 7066 | THPO | S014 | Human | Liver | HCC | 4.07e-19 | 5.66e-01 | 0.2254 |
| 7066 | THPO | S015 | Human | Liver | HCC | 9.22e-19 | 7.45e-01 | 0.2375 |
| 7066 | THPO | S016 | Human | Liver | HCC | 4.82e-17 | 5.01e-01 | 0.2243 |
| 7066 | THPO | S028 | Human | Liver | HCC | 1.13e-09 | 4.30e-01 | 0.2503 |
| 7066 | THPO | S029 | Human | Liver | HCC | 3.71e-13 | 5.18e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003009922 | Liver | HCC | myeloid cell differentiation | 200/7958 | 381/18723 | 4.64e-05 | 4.49e-04 | 200 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| THPO | SNV | Missense_Mutation | rs761351132 | c.481N>T | p.Arg161Cys | p.R161C | P40225 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| THPO | SNV | Missense_Mutation | rs780992873 | c.517N>A | p.Val173Ile | p.V173I | P40225 | protein_coding | deleterious(0.03) | benign(0.003) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| THPO | deletion | Frame_Shift_Del | novel | c.244delN | p.Gln82ArgfsTer7 | p.Q82Rfs*7 | P40225 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| THPO | deletion | Frame_Shift_Del | c.356delN | p.Arg119LeufsTer32 | p.R119Lfs*32 | P40225 | protein_coding | TCGA-E2-A1IG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |||
| THPO | SNV | Missense_Mutation | c.925N>T | p.Leu309Phe | p.L309F | P40225 | protein_coding | deleterious_low_confidence(0.01) | benign(0.041) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| THPO | SNV | Missense_Mutation | rs148499454 | c.914N>T | p.Thr305Met | p.T305M | P40225 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.454) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| THPO | SNV | Missense_Mutation | c.68N>T | p.Pro23Leu | p.P23L | P40225 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| THPO | SNV | Missense_Mutation | novel | c.1041N>T | p.Gln347His | p.Q347H | P40225 | protein_coding | deleterious_low_confidence(0.03) | benign(0.001) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| THPO | SNV | Missense_Mutation | novel | c.551N>T | p.Ser184Ile | p.S184I | P40225 | protein_coding | deleterious(0.01) | possibly_damaging(0.609) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| THPO | SNV | Missense_Mutation | novel | c.429N>T | p.Lys143Asn | p.K143N | P40225 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 7066 | THPO | GROWTH FACTOR, HORMONE ACTIVITY, DRUGGABLE GENOME | SB-224289 | SB-224289 | ||
| 7066 | THPO | GROWTH FACTOR, HORMONE ACTIVITY, DRUGGABLE GENOME | DESIPRAMINE | DESIPRAMINE | ||
| 7066 | THPO | GROWTH FACTOR, HORMONE ACTIVITY, DRUGGABLE GENOME | VANOXERINE | VANOXERINE | ||
| 7066 | THPO | GROWTH FACTOR, HORMONE ACTIVITY, DRUGGABLE GENOME | TERFENADINE | TERFENADINE | ||
| 7066 | THPO | GROWTH FACTOR, HORMONE ACTIVITY, DRUGGABLE GENOME | WIN-55212-2 | WIN-552122 | ||
| 7066 | THPO | GROWTH FACTOR, HORMONE ACTIVITY, DRUGGABLE GENOME | AZACITIDINE | AZACITIDINE | ||
| 7066 | THPO | GROWTH FACTOR, HORMONE ACTIVITY, DRUGGABLE GENOME | PROSTAGLANDIN E1 | 7492761 | ||
| 7066 | THPO | GROWTH FACTOR, HORMONE ACTIVITY, DRUGGABLE GENOME | (R,S)-INDATRALINE | (R,S)-INDATRALINE | ||
| 7066 | THPO | GROWTH FACTOR, HORMONE ACTIVITY, DRUGGABLE GENOME | UREA | UREA | 9726418 | |
| 7066 | THPO | GROWTH FACTOR, HORMONE ACTIVITY, DRUGGABLE GENOME | GENISTEIN | GENISTEIN |
| Page: 1 2 3 4 5 6 7 8 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |